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The GVC (acronym for Gene Vaccination in Cancer) meeting offered the opportunity to continue 
and strengthen the existing national and international collaborations between basic scientists, 
clinical researchers and scientists in industry to overcome obstacles in gene vaccination against 
cancer. The 2013 GVC meeting covered the following topics: (1) New technologies for gene 
vaccination; (2) Emerging targets for cancer vaccines; (3) Therapeutic vaccination against HPV-
dependent diseases; (4) Pre-clinical challenges; (5) Veterinary applications of gene vaccination in 
cancer; (6) In vivo gene-electro-transfer: from technology development to clinical applications. 
 
To provide the broad background for the topics covered by the meeting, two important lectures, one 
on the discovery of tumor associated antigens (TAA) and the other on the importance of tumor-
induced immunoregulatory networks were given by Olivera J. Finn and Vincenzo Bronte, 
respectively. Olivera J. Finn (University of Pittsburgh School of Medicine, Pittsburgh, PA, USA) 
emphasized the critical role of the disease-associated antigens (DAA) that are TAA expressed in 
premalignant lesions or during infections. She pointed to the fact that the efficacy of 
immunotherapy may be greatly improved by vaccinating patients with very early lesions, boosting 
the immunological memory developed against DAA during previous infections. It is thus necessary 
to focus on DAA in order to boost pre-existing responses generated earlier in life. Mucin1 (MUC1) 
is a typical DAA overexpressed in an abnormal hypoglycosylated form in preneoplastic and 
cancerous lesions of various histotypes. A recent clinical study in patients with advanced adenoma 
of the colon showed that anti-MUC1 vaccination was able to elicit anti-MUC1 IgG and long-term 
memory in about 50% of vaccinated patients. Peripheral blood mononuclear cells (PBMC) of non-
responders contained increased levels of myeloid derived suppressor cells (MDSC). The importance 
of modulating MDSC differentiation and activity in the tumor microenvironment in order to obtain 
a good vaccination-induced immune response was further discussed by Vincenzo Bronte 
(University Hospital and Department of Pathology, Verona, Italy) who identified miR-142-3p as a 
master regulator of the expression of the signalling elements of the IL6 receptor and showed that a 
decrease in this miRNA expression is essential in allowing myeloid cells to acquire the suppressive 
phenotype. Moreover, he demonstrated that miR-142-3p can be considered a new target for cancer 
therapy since mice with miR-142-3p constitutive expression in the bone marrow have altered 
tumor-induced macrophage differentiation and display a marked increase in survival following the 
adoptive transfer of tumor-specific T cells. 
 
New technologies for gene vaccination 
In this session, attention was given to the efforts that many companies have done in the design of 
carriers, adjuvants, viral vectors, self amplifying mRNA vaccines and prime and boost strategies to 
be used for anticancer immunotherapy. Ennio De Gregorio (Novartis, Siena, Italy) reported on the 
development of new synthetic compounds optimized to stimulate specific immune cells without 
inducing side effects. A significant increase in vaccine potency and a reduced local and systemic 
reactogenicity was shown by a synthetic compound specific for Toll-like Receptor 7. New mRNA-
based vaccines have also been developed. Of particular note are a non-viral delivery system for self-
amplifying RNA from Novartis that has been successfully tested in pre-clinical models, and the 
RNActive® vaccines reported by Karl-Josef Kallen (CureVac, Tübingen, Germany). RNActive® 
vaccines are two component vaccines engineered in a way that maximises the antigen encoding 
3 
 
properties of mRNA and bestows self-adjuvanticity by activation of TLR7, causing a balanced 
activation of the adaptive and innate immune system. Initial phase I/IIa studies in patients with 
prostate and non-small cell lung cancer (NSCLC), showed that RNActive® vaccines are safe and 
effective in inducing a long lasting, humoral and cellular immune response. Currently, a multi-
center controlled phase IIb study is performed in castrate-resistant prostate cancer in 8 European 
countries to investigate clinical efficacy of RNActive® vaccines and a phase Ib study tests the 
combination of radiotherapy and RNActive® vaccines in metastatic NSCLC. 
 
Emerging targets for cancer vaccines 
Besides the development of more effective gene vaccination technologies, one of the main issues in 
anti-cancer vaccines is still the identification of proper tumor antigen targets. A number of different 
strategies have been used to identify new targets, which include protein kinases, metabolic 
enzymes, chaperone proteins, transporters and angiogenesis related receptors. 
Anaplastic Lymphoma Kinase (ALK) is known to be a good therapeutic target for the treatment of 
anaplastic large cell lymphoma. Claudia Voena (University of Torino, Torino, Italy) and 
coworkers had previously demonstrated that anti-ALK DNA vaccination through electro-
permeabilization (EP) is a good strategy to be used in the treatment of anaplastic large cell 
lymphoma. They reported similar results in the treatment of NSCLC in two independent transgenic 
mouse models of ALK-driven lung cancers that express two different fusions of ALK (EML4-ALK 
and TFG-ALK). It is worth noting that anti-ALK DNA vaccination was also effective against 
tumors harboring ALK mutations that abrogate the efficacy of the ALK inhibitor crisotinib. Voena 
and coworkers also tested the combined administration of anti-ALK DNA EP and crizotinib, 
showing that ALK vaccine could prevent the growth of crizotinib resistant tumors in combined 
therapy. 
The glycolitic enzyme α-enolase is a promising target for the immunotherapy of patients affected 
by pancreatic cancer. It is involved in both growth and metastasis of ductal pancreatic 
adenocarcinoma (PDA). Francesco Novelli (University of Torino, Torino, Italy) and coworkers 
used serological proteomic analysis to discover that patients with PDAC produce antibodies against 
two isoforms of α-enolase, which are also recognized by T lymphocytes. A good correlation 
between these immune responses and prognosis has also been demonstrated. For this reason, a DNA 
vaccine targeting α-enolase has been developed and its administration by EP tested in two 
genetically engineered mouse strains (KrasG12D/Cre mice and KrasG12D/Trp53R172H/Cre mice) that 
develop autochthonous lethal PDA with different kinetics. A specific anti α-enolase antibody and 
cellular immune response were both elicited in vaccinated mice and correlated with an increase in 
their survival times. 
Serenella Pupa (Istituto Nazionale dei Tumori, Milan, Italy) discussed an approach for identifying 
new targets for B-cell non-Hodgkin lymphoma (NHL) immunotherapy. Using sera from autologous 
tumor-loaded dendritic cell from vaccinated NHL responder patients, Pupa and coworkers identified 
the chaperon protein HSP105 as a candidate target for NHL immunotherapy. While in vitro 
administration of a commercial polyclonal anti-HSP105 antibody failed to provide any direct anti-
tumor effect, it significantly reduced tumor burden through antibody-dependent cellular cytotoxicity 
in vivo. Therefore, HSP105 can be added to the list of non-oncogenes that can be exploited as a new 
target for anti-B-cell lymphoma therapy. 
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A growing body of evidence points to cancer tissues being hierarchical systems, where cellular 
heterogeneity is the result of multi-lineage differentiation processes, and tumor progression, 
metastasis, recurrence and resistance to therapy are sustained by a subset of cells with stem cell 
properties, named cancer stem cells (CSC). The identification of molecules involved in CSC self-
renewal is a necessary step towards the development of effective therapies. To this aim, Ronald 
Rooke (Transgene S.A., Illkirch Graffenstaden, France) and Stefania Lanzardo (University of 
Torino, Torino, Italy) presented two different approaches to identifying specific CSC targets in 
glioblastoma and breast cancer, respectively. Rooke used proteomic analysis to identify markers 
overexpressed in neurospheres generated from human samples, while using transcription profile 
analysis of RNA from mammospheres generated from murine breast cancer cells, Lanzardo 
identified cystine/glutamate exchange transporter xCT as overexpressed in breast CSC. EP of a 
plasmid that codes for xCT prevents lung metastasis formation and decreases cancer growth in a 
preclinical model of HER2+ breast cancer. 
Andrea Facciabene (University of Pennsylvania, Philadelphia, PA, USA) reported on the efficacy 
of targeting tumor vasculature as a promising strategy for the treatment of cancer. He showed that 
the EP of a DNA vaccine targeting TEM1 (endosialin, CD284), one of the most abundantly 
expressed tumor endothelial or stromal antigen in humans, is safe and do not affect physiological 
angiogenesis. Moreover, it results in the induction of TEM1-specific T cell-mediated immunity, in 
the disruption of the tumor vasculature and in the induction of tumor necrosis/apoptosis and TAA 
cross-presentation. Combination of TEM1 vaccination with the administration of regulatory T cell 
inhibitors resulted in an increased vaccine efficiency. 
 
Therapeutic vaccination against HPV-dependent diseases 
Two human papillomavirus (HPV) vaccines, which are effective in the prevention but not in the 
treatment of established tumors, are currently on the market. Furthermore, they are expensive and 
not suitable for the use in developing countries. Hence, the development of new vaccines and more 
informative preclinical models are needed. Aldo Venuti (Regina Elena National Cancer Institute, 
Rome, Italy) reported on the new orthotopic mouse models of HPV-associated cancer that can be 
used for testing therapeutic vaccines. By using a combination of a DNA vaccine and a fusion 
protein vaccine produced in plants, he obtained a complete protection against HPV+ head and neck 
orthotopic tumors in vaccinated mice. 
Mark Bagarazzi (Inovio Pharmaceuticals, Blue Bell, PA, USA) reported on the efficacy of, VGX-
3100, a new therapeutic DNA vaccine against HPV-related diseases. This EP administered DNA 
vaccine led to the induction of antigen specific antibodies and T cells in the majority of vaccinated 
patients. In order to significantly increase T cell response, Bagarazzi’s group proposes to combine 
DNA vaccination against HPV with IL-12 administration or with a vaccination against telomerase 
(hTERT), an antigen that is known to be immunogenic, as demonstrated by the presence of existing 
naturally occurring T cell responses in cancer patients. 
 
Pre-clinical challenges 
The improvement of preclinical models of cancer is one of the issues that needs to be dealt with in 
immunotherapy since many of those currently used do not exactly recapitulate human disease. As 
far as breast cancer, emerging evidence suggests that the real transforming form of HER2 is its 
splice variant, the ∆16HER2. Cristina Marchini (University of Camerino, Camerino, Italy) 
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described a new preclinical breast cancer model, the ∆16HER2 transgenic mice that develop 
mammary carcinomas with 100% penetrance. Vaccination of these mice with a plasmid that 
encodes a chimeric human/rat HER2 protein resulted in an effective antitumor response that was 
higher than that induced by vaccination with a plasmid coding for a non chimeric human HER2 
protein. 
Further evidence of the great potential that lies in DNA EP in the field of tumor immunotherapy 
came from data presented by Maarten Ligtenberg (Stockholm, Sweden), who showed that Cripto-
1, a protein involved in cell fate regulation during embryogenesis and in cell proliferation and 
epithelial-mesenchymal transition in several cancers, would present a prime target for DNA 
vaccines. Immunization with mouse and human Cripto-1 generates in vivo protective immune 
responses against Cripto-1+ murine tumors. In order to improve the efficacy of anti-Cripto-1 
vaccination, Ligtenberg pointed out the possibility of modulating the signalling pathways involved 
in T cell activation through the use of shRNA targeting the NF-kB signalling pathway. 
Preclinical evaluation of the safety of therapeutic vaccines to cancer is a relevant issue. Isabella 
Andreini (RTC S.p.A., Pomezia, Italy) emphasized the need of critically interpreting preclinical 
data to obtain correct and useful information for clinical studies and find a compromise between 
regulatory requirements and scientific logic. Indeed, preclinical models have several limitations: 
few animal species are available and animals are young, healthy and inbread, while patients are 
older, sick and genetically heterogeneous. Moreover, the required number of animals is impossible 
to achieve when using primates and there are inter-species differences that may affect results. 
 
Veterinary applications of gene vaccination in cancer 
The use of naturally occurring cancer in pet animals as models of human cancer has gained a 
relevant role in translational medicine over the last decade, and several companion species, such as 
cat, dogs and horses have successfully contributed to this effort. This is due to the striking similarity 
in the histological appearance, tumor genetics, environmental influence, biological behaviour and 
response to therapy between spontaneous tumors diagnosed in pet animal and human tumors. Wei-
Zen Wei (Karmanos Cancer Institute, Detroit, MI, USA) reported on the numerous studies in which 
DNA EP against HER2 was used successfully in murine models but did not lead to effective results 
in human clinical practice. She displayed a comparative study on feline mammary tumors showing 
that HER2 is expressed in 40-85% of them, but it is not amplified. It is very similar in its amino 
acid sequence to the human ortholog and is recognized by antibodies against human HER2. A 
vigorous anti-HER2 immune response after DNA EP with a plasmid coding for a mutated form of 
feline HER2 sequence can be obtained. 
Luigi Aurisicchio (Takis s.r.l., Rome, Italy) reported a double-arm cancer vaccine study based on 
targeting canine telomerase in dogs affected by TERT+ B-cell lymphosarcoma. The combination of 
standard-of-care chemotherapy and heterologous prime/boost, i.e. adenovirus/DNA EP-based 
vaccination, gave a good clinical efficacy in terms of survival of B-cell lymphosarcoma canine 
patients. These data confirm support the evaluation of this approach for other cancer types in 
veterinary field as well as the translation of this approach to human clinical trials. Joe Impellizeri 
(Veterinary Oncology Services, Vassar College, New York, NY, USA) reported additional data 
about an increased survival in dogs affected by B-cell malignant lymphosarcoma when standard of 
care chemotherapy is combined with a genetic vaccine against canine TERT developed by 
Aurisicchio and coworkers. He also reported HER2 immunotherapy trials ongoing with feline 
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mammary cancers and canine osteosarcoma using the same immunotherapy platform (adenovirus 
followed with DNA plasmid via EP). 
Soldano Ferrone (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA) 
described the use of Chondroitin Sulfate Proteoglycan-4 (CSPG4) as a target of antibody-based 
immunotherapy for melanoma patients. Several patients with advanced melanoma have been 
immunized with a CSPG4 mimic and those who developed CSPG4-specific humoral immunity had 
a statistically significant survival prolongation. Human CSPG4 displays more than 80% homology 
with its canine counterpart. This has provided the rationale to use human CSPG4 as immunogen to 
implement active specific immunotherapy in dogs with melanoma, as discussed by Federica 
Riccardo (University of Torino, Torino, Italy). She showed that CSPG4 is expressed by most 
canine malignant melanoma (MM) and can thus be considered a new diagnostic marker and a target 
for cancer immunotherapy. EP of dogs with surgically resected stage II-III CSPG4+ oral MM with a 
plasmid that coded for human CSPG4 resulted in the induction of anti human and canine CSPG4 
antibodies and in a significantly longer overall and disease-free survival time. Therefore, 
xenogeneic vaccination against CSPG4 is able to overcome host unresponsiveness to the self-
antigen and appears to be effective for the treatment of canine MM. 
Philip Bergman (Katonah-Bedford Veterinary Center, Bedford Hills, NY, USA) emphasized that 
the evaluation of genetic cancer vaccines and delivery technologies in pet dogs is a predictive 
model for human clinical trials and a tool to provide novel therapeutic opportunities in veterinary 
oncology. He described the promising results obtained by vaccinating dogs with surgically resected 
stage II-III CMM with the FDA-approved ONCEPT (Merial) vaccine, a plasmid that codes for 
human tyrosinase that is administered intramuscularly with a bio-injector. 
 
In vivo gene-electro-transfer: from technology development to clinical applications 
Several pre-clinical and clinical trials have demonstrated that EP for both gene and chemo transfer 
is safe and well tolerated. Mattia Ronchetti (IGEA S.p.A., Carpi, Italy) reported the efficacy of 
electrochemotherapy in patients with cutaneous cancer manifestation and the ongoing clinical 
validation of a new medical device by IGEA, the Cliniporator™ VITAE, for the treatment of deep 
seated tumor nodules such as bone, liver and soft tissue metastasis. He highlighted the importance 
of using a single EP technology from pre-clinical experiments to clinical trials to reduce the 
regulatory requirements needed to be satisfied for translation to clinical practice. 
Julie Gehl (Copenhagen University Hospital, Herlev, Denmark) discussed that EP conditions must 
be differently optimized for each molecule and for each tissue. A list of the protocols of ECT, 
muscle and skin gene EP for the treatment of several cancers developed by the Center for 
Experimental Drug and Gene Electrotransfer, in the Copenhagen University Hospital, is available at 
http://www.herlevhospital.dk. Interestingly, a clinical brain electrode for ECT has been recently 
developed and approved for trial, and a clinical study for patients suffering from brain metastases 
has commenced. 
The second part of this session was focused on the discussion of new strategies that may enhance 
DNA vaccination efficacy. Emanuela Signori (Institute of Translational Pharmacology, Rome, 
Italy) reported that muscular fiber transfection and consequent antigen expression is significantly 
enhanced by the combination of hyaluronidase administration and DNA EP. These effects rest on 
the ability of the coupled treatment to induce in the vaccinated muscle an early release of 
inflammatory cytokines favouring regeneration of muscle fibers and allowing lower levels of 
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electric fields to be applied. Another important strategy for enhancing vaccination efficacy is the 
use of DNA fusion vaccines. Christian Ottensmeier (University of Southampton, Southampton, 
United Kingdom) reported that DNA vaccines containing tumor antigen sequences fused to 
microbial genes are safe and close to becoming licensed for clinical use. Anti CEA EP vaccinated 
cancer patients showed response induction with preliminary indications of tumor growth 
suppression and evidence for clinically manageable concomitant autoimmunity. A direct correlation 
between the density of the induced effector T tumor infiltrating lymphocytes and a better outcome 
was found in these patients. This suggests that T cells induced by vaccination have an effector 
phenotype. However, often these cells are not able to kill the tumor because they express PD1 on 
their surface. For this reason, the use of anti cancer vaccines in combination with immuno-stimulant 
monoclonal antibodies, are needed. A new promising way to increase antigen immunogenicity is to 
combine peptides of interest with viral particles. These chimeric products can be produced in plants, 
which further increases their immunogenicity. Preclinical testing of these new vaccine products 
resulted in the induction of an effective T cell response and will soon be brought into clinical 
testing. 
 
Special report: the three best abstracts awardees 
A prize was given to three young scientists who contributed to the GVC meeting with a relevant 
poster presentation. The first prize was given to Moitza Principe (University of Torino, Torino, 
Italy), who demonstrated the involvement of the glycolitic enzyme α-enolase in PDA metastasis. 
The second prize was awarded to Giuseppina Barutello (University of Torino, Torino, Italy), who 
demonstrated that maternal immunization against a TAA could offer effective protection to the 
offspring genetically predestined to develop carcinomas and the third prize was given to Caterina 
Bartolacci (University of Camerino, Camerino, Italy) who showed the ability of anti-HER2 
vaccines to inhibit tumor growth in ∆16HER2 transgenic mice. 
 
Conclusions 
The closing lecture delivered by Gennaro Ciliberto (Istituto Nazionale Tumori, Fondazione G. 
Pascale, Naples, Italy) provided an overview of possible future trends in the development of an 
easily scalable vaccination platform technology. Several important points have to be taken into 
account when starting a new cancer vaccine clinical trial. Firstly, the identification of reliable pre-
clinical animal models to test vaccine efficacy is crucial and to this extent the use of pet animals as 
models of human cancer promises to be a successful strategy in translational medicine. Secondly, 
since it is difficult to eradicate a tumor, especially if metastatic, the technology used to treat cancer 
patients should be compatible with prolonged treatment. Thirdly, it is important to combine 
vaccines with other drugs and it is mandatory to find new biomarkers. Ultimately, the best 
vaccination strategy to use depends on the kind of immune response is needed: to elicit an antibody 
response, it is better to use a xenogeneic antigen while to activate T lymphocytes, it is better to use 
a polyepitope vaccine different from the whole antigen. To get both responses a heterologous 
prime-boost strategy might be needed. 
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